2-(5,7-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine | 866319-40-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(5,7-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 2-(5,7-dimethoxy-1H-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine
• CAS: 866319-40-6
• 化学式: C₂₄H₂₁N₃O₄S
• 分子量: 447.514
• InChiKey: AHZYRTIDFQBTLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  94.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(5,7-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 在 sodium hydride 、 potassium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(5,7-dimethoxy-1-methyl-1H-indol-3-yl)-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles

  摘要：

  From an azaindole lead, identified in high throughput screen, a series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co‐crystallization experiments with IGF1‐R.

  DOI：

  10.1111/j.1747-0285.2010.00991.x
• 作为产物：
  描述：

  5,7-二甲氧基-1H-吲哚 在 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 正丁基锂 、 硼酸三甲酯 、 碘 、 碳酸氢钠 、 potassium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-(5,7-dimethoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles

  摘要：

  From an azaindole lead, identified in high throughput screen, a series of potent bis‐azaindole inhibitors of IGF1‐R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co‐crystallization experiments with IGF1‐R.

  DOI：

  10.1111/j.1747-0285.2010.00991.x

文献信息

• Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
  申请人：Wentzler Sylvie

  公开号：US20070093480A1

  公开（公告）日：2007-04-26

  Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.

  化合物的新颖结构如下（I）：或其药学上可接受的盐，其中R、R1、R2、R3、R4、R5和R6的含义如描述中所述，包括所述化合物的药物组合物以及将其用作蛋白激酶抑制剂的用途。
• NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS
  申请人：Wentzler Sylvie

  公开号：US20090233956A1

  公开（公告）日：2009-09-17

  Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.

  化合物的新型式为公式（I）或其药学上可接受的盐，其中R、R1、R2、R3、R4、R5和R6的含义如描述中所给出，药物组成物包括上述化合物，以及其作为蛋白激酶抑制剂的用途。
• Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
  申请人：Aventis Pharma S.A.

  公开号：US07528147B2

  公开（公告）日：2009-05-05

  Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.

  式(I)的新化合物或其药学上可接受的盐，其中R、R1、R2、R3、R4、R5和R6的含义如描述中所示，该化合物的制药组合物以及其作为蛋白激酶抑制剂的用途。
• Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors
  申请人：Aventis Pharma S.A.

  公开号：US07968566B2

  公开（公告）日：2011-06-28

  Novel compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, R4, R5, and R6 have the meanings given in the description, pharmaceutical compositions comprising said compounds and use thereof as protein kinase inhibitors.

  化合物的新颖配方（I）或其药学上可接受的盐，其中R，R1，R2，R3，R4，R5和R6具有描述中给出的含义，包括该化合物的药物组合物以及将其用作蛋白激酶抑制剂的用途。
• NOUVEAUX DERIVES PYRROLO(2,3-B)PYRIDINE, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE COMME INHIBITEURS DE KINASES
  申请人：Aventis Pharma S.A.

  公开号：EP1732546A2

  公开（公告）日：2006-12-20